JAMES WELSH to Antibodies, Monoclonal
This is a "connection" page, showing publications JAMES WELSH has written about Antibodies, Monoclonal.
Connection Strength
0.617
-
Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clin Cancer Res. 2019 12 15; 25(24):7576-7584.
Score: 0.273
-
Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
Score: 0.085
-
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
Score: 0.073
-
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018 11 23; 6(1):128.
Score: 0.064
-
Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7.
Score: 0.053
-
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013 May 15; 119(10):1768-75.
Score: 0.043
-
Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy. 2018 08; 10(10):851-0.
Score: 0.016
-
Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
Score: 0.010